38th EPS
European Peptide Symposium
6 - 11th of September 2026
Vienna, Austria
Sponsor profiles
Agilent
Agilent, a global leader in analytical laboratory technologies, provides trusted answers that help our customers solve their most ambitious scientific challenges, increase laboratory performance, and advance quality of life. Our solutions for pharma and biopharma—from research and drug discovery, to development, manufacturing, and quality control—help to optimize pharma small molecule and biotherapeutic characterization methods, to get products to market faster.
Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe and the US.
BioCat Company
We offer chromatographic analyses as a service to our customers, specializing in the analyses of peptides, amino acid derivatives and other chiral substances. We are inspected by FDA as well as German Authorities.
We offer:
Reliable determination of enantiomeric purity via GC-MS using deuterated reagents and amino acid analysis.
Peptide sequencing and determination of the monoisotopic masses of peptides by high resolution mass spectrometry.
Determination of water content, solvent residues (OVI analysis) and counter ions with minimal sample consumption.
All methods are generically validated. Validation reports can be issued for specific substances.
Fulfillment of the FMP requirements has always been of prime concern in our company.
BioDuro
BioDuro, an Advent International portfolio company, is a global CRDMO with 30 years of experience supporting biotech and pharmaceutical innovators. With 2,000+ scientists across 8 global sites, we provide integrated peptide discovery and development services spanning chemistry, biology, DMPK and CMC. Our peptide capabilities include AI-enabled design, Peptide DEL, Direct-to-Biology, and oral peptide development, supporting programs from early discovery through development and scale-up. Our integrated approach brings scientific disciplines together to address key challenges in peptide design, optimization, bioavailability and developability. With broad capabilities and flexible, tailored programs, BioDuro helps partners accelerate development, reduce risk and advance promising peptide therapeutics toward the clinic.
Biotage
Biotage
Biotage is a global supplier and solutions partner to a wide range of customers within drug discovery and development and analytical testing. With strong expertise in separation and purification technologies, and a focus on leveraging intelligent workflow solutions, we aim to efficiently support the advancement and protection of human health.
CEM
CEM Corporation is a global leader in peptide synthesis technology, providing innovative solutions for research, discovery, and peptide production. From automated microwave peptide synthesis to high-throughput and parallel platforms, CEM systems are designed to accelerate workflows, improve peptide quality, and simplify complex synthesis. CEM also supports manufacturing-scale peptide synthesis with the Liberty PRO, enabling efficient scale-up from development to production. Trusted by leading academic, pharmaceutical, biotechnology, and CRO laboratories worldwide, CEM continues to advance peptide science through intelligent instrumentation, innovative chemistry, and dedicated application support.
CSBio
CSBio is a leading manufacturer of fully automated peptide and oligonucleotide synthesizers, proudly serving the life sciences industry for over 30 years. Our systems have been refined into the flexible, reliable, and cost-effective solutions trusted by researchers and manufacturers worldwide. From research scale to commercial-scale production, CSBio synthesizers are used in top universities, biotech, and pharmaceutical labs across the globe. Today, CSBio is the world’s leading provider of pilot and commercial-scale peptide synthesizers, with more systems in operation than any other manufacturer.
Gyros Protein Technologies
Gyros Protein Technologies has built instruments for automated peptide synthesis since 1985, when it began in Tucson, Arizona.
The PurePep® portfolio runs from method development to clinical material: PurePep® Chorus for modular R&D synthesis, Symphony® X for parallel synthesis with per-channel protocol control, PurePep® Sonata®+ for pilot scale to 200 mmol, and PurePep® EasyClean (PEC™) for purification where HPLC reaches its limits.
Progress depends on synthesis you can trust.
Find us in The Forum, our room on the first floor: a session each day Monday to Wednesday, forty years of the PurePep story, and good coffee. #forpeptidescientists
Gyros Protein Technologies is part of the Biopharmaceutical Development Division of Mesa Laboratories, Inc. (Nasdaq: MLAB).
Iris Biotech
Iris Biotech is providing high quality products for the fields peptide synthesis, linkerology®, drug delivery, and life sciences in flexible quantities from research scale to commercial production, for academia as well as industry. Besides our broad portfolio from standard to exotic, we have the know-how and facilities to manufacture your compound of choice based on a Custom Synthesis.
We are in continuous exchange with scientists all around the world to gather ideas and be ahead regarding technologies and innovations true to our slogan Empowering Peptide Innovation.
All our services are rounded off by a strong and competent personnel customer support.
JPT
For more than 20 years, JPT Peptide Technologies has supported peptide research from discovery to clinical research with high-quality custom solutions manufactured in Berlin under an ISO 9001:2015-certified quality management system. Our expertise spans linear, cyclic, stapled and highly modified peptides, peptide libraries, conjugation-ready and site-specifically functionalized peptides, as well as light and heavy labelled standards. From hit discovery, macrocycle and peptide-drug conjugate development to screening, bioanalysis and preclinical studies, JPT combines flexible synthesis, advanced modifications and application-focused support. Meet us at EPS 2026 in Vienna to discuss your next peptide challenge.
PharmaBlock
PharmaBlock was officially operated in 2008 as a provider of drug-like small molecule building blocks and has since evolved into a fully integrated CRDMO partner following its IPO in 2017 (Stock Code: 300725.SZSE). Today, the company offers end-to-end solutions spanning from early-stage discovery to commercial manufacturing, with expanding capabilities in emerging modalities such as oligonucleotides, peptides, and complex conjugates.
PharmaBlock’s strategy is anchored in advancing sustainability through innovation in green and intelligent chemistry to empower next-generation therapies. In discovery, the company has advanced its building blocks into “PharmaChips” for next generation therapies including novel and high-purity short peptides, amidites and conjugate linkers. Leveraging three distinctive libraries: a DNA-encoded library, a fragment library, and an ultra-large, synthetically accessible virtual library and AI technologies, it enables customers to accelerate hit discovery and lead optimization.
In development, drawing on extensive experience in the production of thousands of building blocks, PharmaBlock has built a strong green and intelligent technology platform for both development and manufacturing. This platform includes flow chemistry, process modeling, computational fluid dynamics (CFD), bio-/metal catalysis, high-throughput experimentation (HTE), process analytical technology (PAT), and digitalization, as well as advanced capabilities in Liquid Phase Peptide Synthesis (LPPS). These capabilities allow the company to address complex chemistry challenges, reduce development risks, and minimize environmental impact.
Committed to green and intelligent chemistry, PharmaBlock combines speed with sustainability. Its global “region-for-region” model ensures fast turnaround, reliable supply, and consistent quality for partners worldwide.
PolyPeptide
PolyPeptide Group is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical through to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with a large exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.
Rapp Polymere
Rapp Polymere is a world leader for high quality polymer supports. We offer a broad range of novel supports. based on TentaGel® or polystyrene. They are used in solid phase chemistry, combinatorial chemistry, as polymer supported reagents, for library generation, peptide and oligonucleotide synthesis, as well as for diagnostic applications. The exceptional properties of the highly swellable TentaGel® XV make this resin the first choice for the synthesis of large peptides and difficult-to-make peptides.
A second line are reagents for PEG´ylation. Our portfolio comprises hundreds of high sophisticated derivatives from Methoxy PEG´s, homofunctional PEG´s to hetero-bifunctional PEG´s. We also offer custom synthesized PEG derivatives and resins.
WuXi TIDES
WuXi TIDES, part of WuXi AppTec, Inc., is an industry-leading, integrated pharmaceutical technology and capability platform, serving the life sciences industry with operations across North America, Europe, and Asia. As an innovative Contract Research, Development and Manufacturing Organization (CRDMO), we provide efficient, flexible, high-quality solutions for our partners worldwide – from discovery to development and commercial supply for oligonucleotides, peptides, and related conjugates.
Zealand Pharma
Zealand Pharma is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Denmark, with a U.S. presence in Massachusetts.
For questions concerning the organization, the program and sponsoring opportunities:
European Peptide Symposium 2026© Copyright 2024 Conference and Event Management of the University of Vienna
